ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Francis Steltz on Aug 12th, 2026

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $28.20.

A number of brokerages have commented on SPRY. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Leerink Partners lowered their price target on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Thursday, June 25th. Finally, Cantor Fitzgerald boosted their price target on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th.

Get Our Latest Stock Report on ARS Pharmaceuticals

ARS Pharmaceuticals Stock Up 0.7%

Shares of SPRY opened at $5.95 on Wednesday. The firm has a fifty day moving average price of $7.75 and a 200-day moving average price of $8.39. The company has a current ratio of 4.94, a quick ratio of 4.77 and a debt-to-equity ratio of 2.79. The firm has a market capitalization of $590.84 million, a P/E ratio of -2.96 and a beta of 0.98. ARS Pharmaceuticals has a 12-month low of $4.91 and a 12-month high of $17.46.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%.The company had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $22.20 million. Equities research analysts expect that ARS Pharmaceuticals will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Alexander A. Fitzpatrick sold 3,355 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $33,550.00. Following the transaction, the insider owned 90,910 shares of the company’s stock, valued at approximately $909,100. This represents a 3.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider owned 12,176 shares in the company, valued at approximately $121,760. This represents a 67.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 33.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SPRY. Royal Bank of Canada increased its position in ARS Pharmaceuticals by 1,075.3% during the 1st quarter. Royal Bank of Canada now owns 18,547 shares of the company’s stock valued at $234,000 after purchasing an additional 16,969 shares during the period. AQR Capital Management LLC purchased a new stake in shares of ARS Pharmaceuticals in the 1st quarter worth approximately $140,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ARS Pharmaceuticals by 13.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 279,840 shares of the company’s stock valued at $3,520,000 after purchasing an additional 32,526 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of ARS Pharmaceuticals by 7.3% during the second quarter. JPMorgan Chase & Co. now owns 34,560 shares of the company’s stock valued at $603,000 after purchasing an additional 2,357 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in ARS Pharmaceuticals by 55.1% during the second quarter. Legal & General Group Plc now owns 54,825 shares of the company’s stock valued at $957,000 after buying an additional 19,484 shares during the period. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals News Roundup

Here are the key news stories impacting ARS Pharmaceuticals this week:

Negative Sentiment: Multiple firms, including Pomerantz, Rosen, Bronstein Gewirtz & Grossman, Kaplan Fox, and others, said a securities class action has been filed on behalf of investors who purchased ARS Pharmaceuticals securities between March 9 and June 24, 2026. The suit alleges violations of federal securities laws, although the notices do not provide detailed findings or establish liability. Pomerantz investor alert
Negative Sentiment: Investors affected during the class period were repeatedly encouraged to contact law firms about seeking lead-plaintiff status. The stated deadline to petition for appointment as lead plaintiff is October 5, 2026, keeping the litigation in the market’s focus in the near term. Faruqi shareholder action reminder
Neutral Sentiment: The numerous announcements largely repeat the same lawsuit and deadline information rather than reporting a new operating or regulatory development. Their volume may amplify headline risk, but the notices alone do not determine the lawsuit’s outcome or quantify potential damages.

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.